

William E Evans

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6861454/william-e-evans-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

456
papers

45,450
citations

108
h-index

206
g-index

487
ext. papers

50,850
ext. citations

8.6
avg, IF

7.2
L-index

#	Paper	IF	Citations
456	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.. <i>Nature Genetics</i> , 2022 , 54, 170-179	36.3	0
455	orter: A Novel Inducible Human CASP1/NALP3/ASC Inflammasome Biosensor.. <i>Journal of Inflammation Research</i> , 2022 , 15, 1183-1194	4.8	
454	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia.. <i>Science Advances</i> , 2022 , 8, eabj1360	14.3	1
453	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 3476-3476	2.2	
452	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 3406-3406	2.2	1
451	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 933-937	9.7	5
450	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. <i>Leukemia</i> , 2021 , 35, 3078-3091	10.7	1
449	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 794-802	6.1	4
448	Improving the treatment of childhood acute lymphoblastic leukemia by optimizing the use of 70-year-old drugs. <i>Haematologica</i> , 2021 , 106, 2794-2796	6.6	1
447	Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. <i>Clinical and Translational Science</i> , 2021 , 14, 1490-1504	4.9	3
446	Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. <i>Cancer</i> , 2021 , 127, 3832-3839	6.4	1
445	Enhancer Hijacking Drives Oncogenic Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 2846-2867	24.4	12
444	Effects of NT5C2 Germline Variants on 6-Mercaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1538-1545	6.1	1
443	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 408-417	9.7	7
442	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021 , 2, 284-299	15.4	19
441	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. <i>Pharmacogenetics and Genomics</i> , 2021 ,	1.9	1
440	Concordance between Self-reported Symptoms and Clinically Ascertained Peripheral Neuropathy among Childhood Cancer Survivors: the St. Jude Lifetime Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2256-2267	4	1

439	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	6
438	Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid-resistant from glucocorticoid-sensitive idiopathic nephrotic syndrome patients. <i>Clinical and Translational Science</i> , 2021 , 14, 964-975	4.9	6
437	New insights into methotrexate accumulation in leukemia cells. <i>Molecular and Cellular Oncology</i> , 2021 , 8, 1865086	1.2	1
436	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020 , 1, 329-344	15.4	19
435	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. <i>Cancers</i> , 2020 , 12,	6.6	6
434	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. <i>Blood Cancer Discovery</i> , 2020 , 1, 96-111	7	44
433	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6600-6615	15.9	6
432	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28040	3	22
431	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 176-180	6.1	13
430	Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 256-264	12.9	10
429	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 361-374	3.5	6
428	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2020 , 9, 6550-6555	4.8	3
427	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2051-2061	2.2	46
426	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. <i>PLoS ONE</i> , 2019 , 14, e0216328	3.7	4
425	Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. <i>BMC Cancer</i> , 2019 , 19, 253	4.8	15
424	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1350-1357	9.7	19
423	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3377-3391	2.2	75
422	Clinical Pharmacodynamics of Anticancer Drugs 2019 , 389-414		

421 Pharmacogenomics **2019**, 339-352

420	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 649-649	2.2	2
419	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. <i>Nature Communications</i> , 2019 , 10, 5348	17.4	29
418	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy: Progress Continues. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 315-317	6.1	12
417	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1095-1105	6.1	247
416	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019 , 51, 296-307	36.3	189
415	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019 , 133, 724-729	2.2	29
414	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018 , 33, 937-948.e8	24.3	98
413	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 23-54	2.2	13
412	Pharmacogenomics and Hematologic Diseases 2018 , 79-91		
411	Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. <i>SLAS Discovery</i> , 2018 , 23, 164-173	3.4	14
410	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. <i>Blood</i> , 2018 , 132, 2697-2697	2.2	1
409	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 565-565	2.2	1
408	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 2665-2665	2.2	
407	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018 , 36, 591-599	2.2	85
406	Peripheral neuropathy in children and adolescents treated for cancer. <i>The Lancet Child and Adolescent Health</i> , 2018 , 2, 744-754	14.5	22
405	Multiplex assessment of protein variant abundance by massively parallel sequencing. <i>Nature Genetics</i> , 2018 , 50, 874-882	36.3	163
404	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017 , 129, 1919-1926	2.2	21

403	Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 287-293	3.5	7
402	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017 , 27, 294-302	1.9	11
401	A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. <i>Cancer Management and Research</i> , 2017 , 9, 397-410	3.6	3
400	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1730-1736	2.2	17
399	Novel variants in and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. <i>Blood</i> , 2017 , 130, 1209-1212	2.2	65
398	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. <i>Leukemia</i> , 2017 , 31, 333-339	10.7	90
397	An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 391-395	6.1	39
396	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10514-10514	2.2	14
395	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016 , 48, 1481-1489	36.3	145
394	Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. <i>Molecular and Cellular Oncology</i> , 2016 , 3, e1065947	1.2	6
393	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nature Genetics</i> , 2016 , 48, 367-73	36.3	285
392	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016 , 128, 1085-1085	2.2	1
391	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. <i>PLoS Computational Biology</i> , 2016 , 12, e1004744	5	44
390	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 179-179	2.2	
389	Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion, and altered sensory function in mice. <i>Scientific Reports</i> , 2016 , 6, 30757	4.9	2
388	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2133-40	2.2	57
387	Effect of premedications in a murine model of asparaginase hypersensitivity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 352, 541-51	4.7	12
386	The genomic landscape of childhood and adolescent melanoma. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 816-823	4.3	121

385	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015 , 6, 7553	17.4	51
384	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 815-23	27.4	179
383	Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1235-42	2.2	278
382	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. <i>Nature Genetics</i> , 2015 , 47, 607-14	36.3	96
381	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology, The</i> , 2015 , 16, 465-74	21.7	118
380	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology, The</i> , 2015 , 16, 1659-66	21.7	123
379	Pharmacogenomics in the clinic. <i>Nature</i> , 2015 , 526, 343-50	50.4	455
378	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2938-48	2.2	509
377	Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015 , 55, 89-106	17.9	292
376	BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. <i>Haematologica</i> , 2015 , 100, e354-7	6.6	61
375	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. <i>Blood</i> , 2015 , 126, 2896-9	2.2	62
374	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015 , 125, 680-6	2.2	84
373	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 126, 1770-6	2.2	86
372	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>JAMA Oncology</i> , 2015 , 1, 287-95	13.4	84
371	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015 , 126, 69-75	2.2	54
370	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. <i>Blood</i> , 2015 , 126, 3714-3714	2.2	2
369	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 693-693	2.2	1
368	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. <i>Blood</i> , 2015 , 126, 82-82	2.2	3

367	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2015 , 10, e0135134	3.7	13
366	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1421-1421	2.2	1
365	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1299-1299	2.2	
364	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 692-692	2.2	1
363	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 695-695	2.2	
362	Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2014 , 32, 949-59	2.2	190
361	PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014 , 166C, 45-55	3.1	169
360	Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3012-20	2.2	190
359	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. <i>Pharmacogenomics</i> , 2014 , 15, 1065-78	2.6	41
358	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1005-15	59.2	885
357	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2014 , 124, 2345-53	2.2	123
356	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014 , 124, 1266-76	2.2	70
355	Development and use of active clinical decision support for preemptive pharmacogenomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, e93-9	8.6	148
354	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 263-71	1.9	8
353	Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. <i>Journal of Biological Chemistry</i> , 2014 , 289, 20502-15	5.4	44
352	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014 , 124, 367-367	2.2	1
351	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. <i>Blood</i> , 2014 , 124, 791-791	2.2	2
350	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10013-10013	2.2	2

349	A Murine Model of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 2295-2295	2.2	
348	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014 , 124, 63-63	2.2	
347	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014 , 124, 3722-3722	2.2	
346	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Blood</i> , 2014 , 124, 132-132	2.2	0
345	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2014 , 124, 369-369	2.2	
344	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 3701-3701	2.2	1
343	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 369-78	3.5	26
342	A 50-year journey to cure childhood acute lymphoblastic leukemia. <i>Seminars in Hematology</i> , 2013 , 50, 185-96	4	195
341	A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 224-9	6.1	15
340	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 290-4	36.3	216
339	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 207-10	6.1	128
338	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013 , 45, 1494-8	36.3	205
337	Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 93, 324-5	6.1	263
336	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 733-42	9.7	167
335	Mathematical modeling of folate metabolism. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013 , 5, 603-13	6.6	5
334	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013 , 121, 898-904	2.2	137
333	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. <i>Blood</i> , 2013 , 122, 2622-9	2.2	205
332	Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 242-8	1.9	79

331	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. <i>Haematologica</i> , 2013 , 98, 1905-11	6.6	18
330	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Children's Oncology Group (COG) Study (AALL03N1). <i>Blood</i> , 2013 , 122, 59-59	2.2	3
329	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 60-60	2.2	1
328	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 618-618	2.2	5
327	BCR-ABL1-Like Cases In Pediatric Acute Lymphoblastic Leukemia: A Comparison Between COG/St. Jude and Dutch DCOG Signatures. <i>Blood</i> , 2013 , 122, 2633-2633	2.2	
326	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 119, 1658-64	2.2	67
325	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 4197-204	2.2	89
324	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2012 , 22, 153-66	24.3	515
323	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. <i>Leukemia</i> , 2012 , 26, 2303-9	10.7	83
322	The Pediatric Cancer Genome Project. <i>Nature Genetics</i> , 2012 , 44, 619-22	36.3	239
321	Pharmacogenomics and individualized medicine: translating science into practice. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 467-75	6.1	148
320	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012 , 481, 157-63	50.4	1163
319	Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. <i>Blood</i> , 2012 , 120, 1165-74	2.2	383
318	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. <i>Human Molecular Genetics</i> , 2012 , 21, 4793-804	5.6	47
317	Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2005-12	2.2	87
316	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 751-7	2.2	131
315	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. <i>Leukemia</i> , 2012 , 26, 265-70	10.7	80
314	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. <i>Genome Research</i> , 2012 , 22, 1-8	9.7	177

313	Culture trumps strategy: we must encourage the next generation of pharmacists to keep looking over the horizon and not be limited by what they can see today. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012 , 52, 450-3	1.7	1
312	A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 563-6	6.1	87
311	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012 , 120, 2466-2466	2.2	1
310	Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Can Be Synergistically Overcome by Inhibition of Anti-Apoptotic MCL1 and Glycolysis. <i>Blood</i> , 2012 , 120, 3528-3528	2.2	1
309	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 878-878	2.2	
308	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 530-530	2.2	1
307	The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia. <i>Blood</i> , 2012 , 120, 1465-1465	2.2	
306	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Blood</i> , 2012 , 120, 877-877	2.2	0
305	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. <i>Blood</i> , 2012 , 120, 3560-3560	2.2	
304	Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 880-880	2.2	
303	Cancer pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 90, 461-6	6.1	31
302	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. <i>International Journal of Data Mining and Bioinformatics</i> , 2011 , 5, 143-57	0.5	11
301	PharmGKB summary: methotrexate pathway. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 679-86	1.9	93
300	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2011 , 117, 2340-7; quiz 2556	2.2	185
299	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2011 , 43, 237-41	36.3	201
298	Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 387-91	6.1	433
297	A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. <i>Leukemia</i> , 2011 , 25, 66-74	10.7	45
296	Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1771-8	2.2	38

295	Improved prognosis for older adolescents with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 386-91	2.2	102
294	Reply to B.A. Kamen et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3494-3495	2.2	
293	Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. <i>Nature Medicine</i> , 2011 , 17, 1298-303	50.5	95
292	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. <i>Blood</i> , 2011 , 118, 571-571	2.2	
291	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 2550-2550	2.2	
290	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011 , 118, 68-68	2.2	
289	Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target. <i>Blood</i> , 2011 , 118, 1476-1476	2.2	
288	Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2010 , 88, 191-6	6.1	61
287	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2010 , 24, 371-82	10.7	216
286	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. <i>Leukemia</i> , 2010 , 24, 894-6	10.7	70
285	Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. <i>Expert Opinion on Drug Safety</i> , 2010 , 9, 23-37	4.1	48
284	Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. <i>PLoS Computational Biology</i> , 2010 , 6, e1001019	5	35
283	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. <i>Lancet Oncology, The</i> , 2010 , 11, 507-9	21.7	82
282	Pharmacogenomics in pediatric leukemia. <i>Current Opinion in Pediatrics</i> , 2010 , 22, 703-10	3.2	24
281	Thiopurine pathway. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 573-4	1.9	71
280	Epigenetic Regulation of Human Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. <i>American Journal of Human Genetics</i> , 2010 , 87, 161	11	78
279	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2010 , 116, 1033-1033	2.2	1
278	VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010 , 116, 273-273	2.2	4

277	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010 , 116, 8-8	2.2	
276	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 498-498		
275	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010 , 116, 495-495	2.2	
274	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing 2009 ,		1
273	Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 393-403	27.4	174
272	Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5972-8	2.2	269
271	TPMT genetic variations in populations of the Russian Federation. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 203-8	3	20
270	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. <i>Leukemia</i> , 2009 , 23, 1406-9	10.7	100
269	Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 164-72	6.1	168
268	Germline genomic variants associated with childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009 , 41, 1001-5	36.3	383
267	Treating childhood acute lymphoblastic leukemia without cranial irradiation. <i>New England Journal of Medicine</i> , 2009 , 360, 2730-41	59.2	868
266	Pharmacogenetics in acute lymphoblastic leukemia. <i>Seminars in Hematology</i> , 2009 , 46, 39-51	4	46
265	A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. <i>Lancet Oncology, The</i> , 2009 , 10, 125-34	21.7	665
264	High-dose methotrexate: the rationale. <i>Journal of Pediatric Hematology/Oncology</i> , 2009 , 31, 224-5	1.2	2
263	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. <i>Blood</i> , 2009 , 113, 2014-21	2.2	162
262	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. <i>Blood</i> , 2009 , 113, 4512-20	2.2	45
261	Chemotherapy in the Pediatric Patient 2009 , 173-207		0
260	Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). <i>Journal of Clinical Oncology</i> , 2009 , 27, s3-s3	2.2	

259	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2009 , 114, 112-112	2.2	
258	The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1792-803	9.7	50
257	Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 130-1		2
256	Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. <i>Cancer Research</i> , 2008 , 68, 4983-9	10.1	117
255	In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. <i>PLoS Medicine</i> , 2008 , 5, e83	11.6	60
254	Continue to study childhood ALL. <i>Blood</i> , 2008 , 111, 468-9; author reply 469	2.2	1
253	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2008 , 112, 4178-83	2.2	157
252	Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. <i>PLoS ONE</i> , 2008 , 3, e2144	3.7	6
251	Modulation of the Glycolysis Pathway Reverses Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 2008 , 112, 17-17	2.2	2
250	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008 , 112, 14-14	2.2	0
249	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. <i>Blood</i> , 2008 , 112, 214-214	2.2	
248	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. <i>Nature</i> , 2007 , 446, 758-64	30.4	1398
247	John H. Rodman, Pharm.D., FCCP: January 6, 1946-April 29, 2006. <i>Pharmacotherapy</i> , 2007 , 27, 1-2	5.8	
246	Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. <i>Cancer Research</i> , 2007 , 67, 4965-72	10.1	32
245	Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1207-15	27.4	226
244	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. <i>Human Molecular Genetics</i> , 2007 , 16, 2261-71	5.6	35
243	Ancestry and pharmacogenetics of antileukemic drug toxicity. <i>Blood</i> , 2007 , 109, 4151-7	2.2	166
242	Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype. <i>Blood</i> , 2007 , 110, 2887-2897	2.2	

241	Creating an infrastructure for pediatric oncology drug development. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 198-200	0.6	
240	Pharmacogenomics of acute leukemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2006 , 46, 317-53	17.9	28
239	Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2431-2	1.9	8
238	Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. <i>American Journal of Human Genetics</i> , 2006 , 79, 264-74	11	26
237	Treatment of acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2006 , 354, 166-78	59.2	1493
236	The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2006 , 107, 769-76	2.2	107
235	Thiopurine methyltransferase in acute lymphoblastic leukemia. <i>Blood</i> , 2006 , 107, 843-4	2.2	107
234	Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. <i>Blood</i> , 2006 , 108, 1984-90	2.2	19
233	Pharmacogenomics of acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 2006 , 13, 260-5	3.3	21
232	Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. <i>Nature Reviews Cancer</i> , 2006 , 6, 117-29	31.3	180
231	Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. <i>European Journal of Human Genetics</i> , 2006 , 14, 991-8	5.3	28
230	Pharmacogenomics and individualized drug therapy. <i>Annual Review of Medicine</i> , 2006 , 57, 119-37	17.4	486
229	Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006 , 108, 217-217	2.2	
228	Cancer pharmacogenomics may require both qualitative and quantitative approaches. <i>Cell Cycle</i> , 2005 , 4, 1506-9	4.7	8
227	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 4752-8	2.2	182
226	Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 4223-5	2.2	60
225	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. <i>Blood</i> , 2005 , 106, 1778-85	2.2	46
224	Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. <i>Nature Genetics</i> , 2005 , 37, 878-82	36.3	63

223	Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2005 , 7, 375-86	24.3	139
222	Lymphoid gene expression as a predictor of risk of secondary brain tumors. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 107-16	5	27
221	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2005 , 103, 368-76	6.4	73
220	Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7936-41	2.2	64
219	Global gene expression as a function of germline genetic variation. <i>Human Molecular Genetics</i> , 2005 , 14, 1621-9	5.6	14
218	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. <i>Journal of Clinical Investigation</i> , 2005 , 115, 110-7	15.9	108
217	A journey from pediatric pharmacokinetics to pharmacogenomics. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2005 , 10, 8-13	1.6	3
216	Haplotype Structure and Pharmacogenomics. <i>Drugs and the Pharmaceutical Sciences</i> , 2005 , 441-459		
215	Gene expression microarrays as a prognostic test. <i>Clinical Advances in Hematology and Oncology</i> , 2005 , 3, 902-4	0.6	1
214	A novel CRM1-mediated nuclear export signal governs nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase following genotoxic stress. <i>Journal of Biological Chemistry</i> , 2004 , 279, 5984-92	5.4	67
213	Moving towards individualized medicine with pharmacogenomics. <i>Nature</i> , 2004 , 429, 464-8	50.4	583
212	Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2004 , 43, 103-4	3	13
211	Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. <i>New England Journal of Medicine</i> , 2004 , 351, 533-42	59.2	492
210	Pharmacogenomics in cancer therapy: is host genome variability important?. <i>Trends in Pharmacological Sciences</i> , 2004 , 25, 457-64	13.2	30
209	Closing the gap between science and clinical practice: the thiopurine S-methyltransferase polymorphism moves forward. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 395-6		7
208	A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 557-67		69
207	Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 186-91	3.2	160
206	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. <i>Blood</i> , 2004 , 104, 1435-41	2.2	35

205	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIII B at St Jude Children's Research Hospital. <i>Blood</i> , 2004 , 104, 2690-6	2.2	366
204	Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. <i>Blood</i> , 2004 , 104, 1959-1959		
203	Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.. <i>Blood</i> , 2004 , 104, 144-144	2.2	
202	Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2004 , 104, 1964-1964	2.2	
201	Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2 ^{-/-} mice. <i>Molecular Pharmacology</i> , 2003 , 64, 456-65	4.3	10
200	Results of therapy for acute lymphoblastic leukemia in black and white children. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2001-7	27.4	126
199	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. <i>Blood</i> , 2003 , 101, 3862-7	2.2	122
198	Expression arrays illuminate a way forward for mantle cell lymphoma. <i>Cancer Cell</i> , 2003 , 3, 100-2	24.3	4
197	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, 506-16	6.1	14
196	Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. <i>Leukemia</i> , 2003 , 17, 700-6	10.7	176
195	Drug methylation in cancer therapy: lessons from the TPMT polymorphism. <i>Oncogene</i> , 2003 , 22, 7403-13	9.2	107
194	Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. <i>Nature Genetics</i> , 2003 , 34, 85-90	36.3	220
193	Pharmacogenomics--drug disposition, drug targets, and side effects. <i>New England Journal of Medicine</i> , 2003 , 348, 538-49	59.2	1383
192	Structure and dynamics of thioguanine-modified duplex DNA. <i>Journal of Biological Chemistry</i> , 2003 , 278, 1005-11	5.4	79
191	Pharmacogenomics: marshalling the human genome to individualise drug therapy. <i>Gut</i> , 2003 , 52 Suppl 2, ii10-8	19.2	29
190	Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2003 , 349, 640-9	59.2	355
189	A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. <i>Cancer Research</i> , 2003 , 63, 100-6	10.1	83
188	Childhood acute lymphoblastic leukemia. <i>Reviews in Clinical and Experimental Hematology</i> , 2002 , 6, 161-80; discussion 200-2		35

187	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 419-28	3.5	35
186	Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2959-64	2.2	82
185	Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 421-3		24
184	Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 93-9		70
183	Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 181-2		21
182	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 100, 43-7	2.2	39
181	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. <i>Blood</i> , 2002 , 100, 1240-7	2.2	80
180	Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002 , 15, 741-56	4.2	37
179	Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. <i>Trends in Molecular Medicine</i> , 2002 , 8, 300-5	11.5	48
178	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. <i>Cancer Cell</i> , 2002 , 1, 133-43	24.3	1541
177	HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. <i>Clinical Chemistry</i> , 2002 , 48, 61-68	5.5	42
176	Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations. <i>Journal of Pediatric Hematology/Oncology</i> , 2002 , 24, 335-6	1.2	11
175	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. <i>Clinical Chemistry</i> , 2002 , 48, 61-8	5.5	14
174	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. <i>Clinical Cancer Research</i> , 2002 , 8, 2423-9	12.9	33
173	Second malignancy after treatment of childhood non-Hodgkin lymphoma. <i>Cancer</i> , 2001 , 92, 1959-66	6.4	51
172	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. <i>FASEB Journal</i> , 2001 , 15, 1902-8	0.9	13
171	Pharmacogenomics: unlocking the human genome for better drug therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2001 , 41, 101-21	17.9	267
170	Pharmacodynamics of cancer chemotherapy: childhood ALL as a model. <i>International Congress Series</i> , 2001 , 1220, 203-222		

169	Pharmacogenomics: the inherited basis for interindividual differences in drug response. <i>Annual Review of Genomics and Human Genetics</i> , 2001 , 2, 9-39	9.7	302
168	Childhood acute lymphoblastic leukaemia--current status and future perspectives. <i>Lancet Oncology, The</i> , 2001 , 2, 597-607	21.7	217
167	A novel protein complex distinct from mismatch repair binds thioguanylated DNA. <i>Molecular Pharmacology</i> , 2001 , 59, 367-74	4.3	50
166	Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2293-301	2.2	351
165	Resequencing the sulfotransferase <i>SULT1</i> gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 745-6		4
164	Unravelling the functional genomics of the human <i>CYP2D6</i> gene locus. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 553-4		34
163	Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. <i>Pharmacology</i> , 2000 , 61, 136-46	2.3	130
162	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2000 , 14, 567-72	10.7	380
161	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. <i>Leukemia</i> , 2000 , 14, 2286-94	10.7	175
160	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 96, 3381-3384	2.2	149
159	Late effects of treatment in survivors of childhood acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3273-9	2.2	170
158	Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1525-32	2.2	131
157	Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. <i>Lancet, The</i> , 2000 , 356, 285-90	4.0	159
156	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2000 , 96, 3381-3384	2.2	13
155	Acute lymphoblastic leukemia in infants. <i>Journal of Clinical Oncology</i> , 1999 , 17, 438-40	2.2	26
154	Sex differences in prognosis for children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1999 , 17, 818-24	2.2	103
153	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999 , 93, 2817-2823	2.2	306
152	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. <i>Blood</i> , 1999 , 93, 1643-1650	2.2	98

151	Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 2001-8	9.7	589
150	Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. <i>Human Molecular Genetics</i> , 1999 , 8, 371-6	5.6	196
149	An interview with a distinguished pharmaceutical scientist. William E. Evans. <i>Pharmaceutical Research</i> , 1999 , 16, 785-9	4.5	1
148	Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. <i>Pharmaceutical Research</i> , 1999 , 16, 342-9	4.5	90
147	Pharmacogenomics: translating functional genomics into rational therapeutics. <i>Science</i> , 1999 , 286, 487-91	35.3	1986
146	High incidence of secondary brain tumours after radiotherapy and antimetabolites. <i>Lancet, The</i> , 1999 , 354, 34-9	40	341
145	Synthesis of modified thiopurine nucleosides for structural characterization of human thiopurine S-methyltransferase. <i>Nucleosides & Nucleotides</i> , 1999 , 18, 1747-8		3
144	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 641-650		29
143	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. <i>Blood</i> , 1999 , 93, 1643-1650	2.2	3
142	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. <i>Blood</i> , 1999 , 93, 2817-2823	2.2	30
141	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 641-50	1.9	77
140	Genetic abnormalities and drug resistance in acute lymphoblastic leukemia. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 457, 383-9	3.6	7
139	Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic. <i>Advances in Experimental Medicine and Biology</i> , 1999 , 457, 537-41	3.6	4
138	Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 46-51	6.1	67
137	Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. <i>Leukemia</i> , 1998 , 12, 346-52	10.7	166
136	Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. <i>FEBS Journal</i> , 1998 , 256, 510-7		26
135	Molecular cloning and functional characterization of the cDNA encoding the murine thiopurine S-methyltransferase (TPMT). <i>FEBS Letters</i> , 1998 , 424, 143-5	3.8	8
134	Pharmacogenetics of cancer therapy: getting personal. <i>American Journal of Human Genetics</i> , 1998 , 63, 11-6	11	126

133	Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1998 , 338, 499-505	59.2	396
132	Acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1998 , 339, 605-15	59.2	743
131	In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate. <i>Leukemia and Lymphoma</i> , 1998 , 30, 389-94	1.9	9
130	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3768-73	2.2	82
129	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 92, 411-415	2.2	170
128	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998 , 92, 411-415	2.2	6
127	Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic leukemia as a model. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 453-8	3.2	4
126	Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1997 , 336, 1781-7	59.2	138
125	Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997 , 94, 6444-9	11.5	234
124	Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. <i>Annals of Internal Medicine</i> , 1997 , 126, 608-14	8	566
123	Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. <i>Molecular Pharmacology</i> , 1997 , 52, 155-63	4.3	89
122	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1150-7	2.2	176
121	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997 , 89, 1701-1707	2.2	233
120	Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. <i>Leukemia</i> , 1997 , 11, 1813-6	10.7	134
119	Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?. <i>Leukemia Research</i> , 1997 , 21, 435-7	2.7	13
118	Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. <i>Pharmaceutical Research</i> , 1997 , 14, 1672-8	4.5	36
117	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1997 , 89, 1701-1707	2.2	6
116	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1504-11	2.2	57

115	Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 399-404	2.2	57
114	Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2370-6	2.2	115
113	Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 279-90		226
112	Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. <i>Medical and Pediatric Oncology</i> , 1996 , 26, 85-9		30
111	Hepatic drug clearance in patients with mild cystic fibrosis. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 529-40	6.1	16
110	Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. <i>Journal of Clinical Investigation</i> , 1996 , 97, 73-80	15.9	153
109	Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia. <i>Hamatologie Und Bluttransfusion</i> , 1996 , 62-66		
108	Ligation of CD38 suppresses human B lymphopoiesis. <i>Journal of Experimental Medicine</i> , 1995 , 181, 1101-106		132
107	Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. <i>Leukemia and Lymphoma</i> , 1995 , 18, 93-102	1.9	10
106	Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. <i>Science</i> , 1995 , 267, 886-91	33.3	241
105	A longitudinal study of granulocyte colony-stimulating factor levels and neutrophil counts in newborn infants. <i>Journal of Pediatric Hematology/Oncology</i> , 1995 , 17, 176-9	1.2	10
104	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 281-6		67
103	A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 949-53	11.5	291
102	Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 824-8	3.9	25
101	Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 1994 , 94, 1996-2001	15.9	150
100	Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. <i>Human Molecular Genetics</i> , 1994 , 3, 923-6	5.6	91
99	High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. <i>Annals of Neurology</i> , 1994 , 36, 920-4	9.4	55
98	Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. <i>Leukemia Research</i> , 1994 , 18, 811-4	2.7	20

97	Thiopurine methyltransferase activity in American white subjects and black subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 55, 15-20	6.1	226
96	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1994 , 125, 642-9	3.6	102
95	Patient characteristics associated with high-risk methotrexate concentrations and toxicity. <i>Journal of Clinical Oncology</i> , 1994 , 12, 1667-72	2.2	161
94	Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. <i>Journal of Pediatrics</i> , 1993 , 123, 471-9	3.6	51
93	Alternative approaches for Phase I studies of anticancer drugs: a role for therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , 1993 , 15, 492-7	3.2	10
92	Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. <i>Journal of Clinical Oncology</i> , 1993 , 11, 287-93	2.2	24
91	Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. <i>Journal of Clinical Investigation</i> , 1993 , 91, 2150-4	15.9	64
90	Increased teniposide clearance with concomitant anticonvulsant therapy. <i>Journal of Clinical Oncology</i> , 1992 , 10, 311-5	2.2	67
89	Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 643-58	6.1	262
88	Factors affecting in vitro protein binding of etoposide in humans. <i>Journal of Pharmaceutical Sciences</i> , 1992 , 81, 259-64	3.9	10
87	Aspirin alters methotrexate disposition in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1514-20		51
86	Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 132-40	6.1	42
85	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 308-13	6.1	92
84	Relation of systemic exposure to unbound etoposide and hematologic toxicity. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 385-93	6.1	79
83	Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. <i>Medical and Pediatric Oncology</i> , 1991 , 19, 153-9		27
82	Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 27, 397-400	3.5	6
81	Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 1991 , 325, 1682-7	59.2	599
80	Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1991 , 119, 985-9	3.6	365

79	Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. <i>Lancet, The</i> , 1991 , 337, 61-6	4.0	292
78	Lipoprotein analysis in the evaluation of chest pain in the emergency department. <i>Mayo Clinic Proceedings</i> , 1991 , 66, 885-91	6.4	6
77	Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1341-7	2.2	26
76	Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1022-8	2.2	75
75	Targeted Systemic Exposure for Pediatric Cancer Therapy 1991 , 177-183		2
74	Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 1990 , 47, 540-6	6.1	52
73	Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. <i>Cancer</i> , 1990 , 65, 439-45	6.4	43
72	Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. <i>Journal of Clinical Oncology</i> , 1990 , 8, 1874-9	2.2	64
71	Enhanced hepatic drug clearance in patients with cystic fibrosis. <i>Journal of Pediatrics</i> , 1990 , 117, 972-9	3.6	38
70	Advances in pediatric pharmacokinetics and therapeutics. <i>Journal of Pediatrics</i> , 1990 , 117, 996-1001	3.6	2
69	Synthesis of potential antifilarial agents 2 . methyl 2-substituted purine 8-carbamates and related compounds. <i>Journal of Heterocyclic Chemistry</i> , 1989 , 26, 1053-1059	1.9	5
68	Hepatic drug clearance in children: studies with indocyanine green as a model substrate. <i>Journal of Pharmaceutical Sciences</i> , 1989 , 78, 452-6	3.9	25
67	Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. <i>Biomedical Applications</i> , 1989 , 491, 501-6		6
66	Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 568-73	6.1	82
65	Altered protein binding of etoposide in patients with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 49-55	6.1	71
64	Lorazepam pharmacodynamics and pharmacokinetics in children. <i>Journal of Pediatrics</i> , 1989 , 114, 641-6	3.6	27
63	Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. <i>Clinical Pharmacokinetics</i> , 1989 , 16, 327-36	6.2	94
62	Clinical pharmacology of cancer chemotherapy in children. <i>Pediatric Clinics of North America</i> , 1989 , 36, 1199-230	3.6	28

61	Anticancer therapy as a pediatric pharmacodynamic paradigm. <i>Developmental Pharmacology and Therapeutics</i> , 1989 , 13, 85-95		6
60	Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. <i>Cancer</i> , 1988 , 62, 884-8	6.4	63
59	High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. <i>Medical and Pediatric Oncology</i> , 1988 , 16, 297-303		43
58	Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. <i>Blut</i> , 1988 , 56, 241-8		34
57	Drug Concentration Monitoring. <i>Progress in Clinical Biochemistry and Medicine</i> , 1988 , 1-16		
56	Academic research fellowships in clinical pharmacy. <i>Drug Intelligence & Clinical Pharmacy</i> , 1987 , 21, 106-9		
55	Methotrexate bioavailability after oral and intramuscular administration in children. <i>Journal of Pediatrics</i> , 1987 , 110, 788-92	3.6	57
54	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. <i>Journal of Pediatrics</i> , 1987 , 111, 606-12	3.6	85
53	Pharmacokinetics of anticancer drugs in children. <i>Clinical Pharmacokinetics</i> , 1987 , 12, 168-213	6.2	54
52	Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. <i>Journal of Clinical Oncology</i> , 1987 , 5, 1007-14	2.2	93
51	Simultaneous administration of multiple model substrates to assess hepatic drug clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 645-50	6.1	34
50	Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 651-60	6.1	34
49	Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults 1987 , 29-71		
48	Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1986 , 382, 199-205		12
47	Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 592-7	6.1	11
46	Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. <i>New England Journal of Medicine</i> , 1986 , 314, 471-7	59.2	313
45	Etoposide pharmacokinetics in patients with normal and abnormal organ function. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1690-5	2.2	75
44	Loop-column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma. <i>Therapeutic Drug Monitoring</i> , 1985 , 7, 455-60	3.2	18

43	High-performance liquid chromatographic assay of mitomycin in biological fluids. <i>Biomedical Applications</i> , 1985 , 345, 197-202		11
42	Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1985 , 3, 201-6	2.2	29
41	The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. <i>Journal of Clinical Oncology</i> , 1984 , 2, 655-61	2.2	38
40	High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. <i>Journal of Pharmaceutical Sciences</i> , 1984 , 73, 164-8	3.9	46
39	High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides. <i>Biomedical Applications</i> , 1983 , 274, 87-93		20
38	Pharmacokinetics of anticancer drugs in children. <i>Drug Metabolism Reviews</i> , 1983 , 14, 847-86	7	20
37	A simple preparation of the methotrexate metabolites 7-hydroxymethotrexate and 4-deoxy-4-amino-N10-methylpterotic acid. <i>Therapeutic Drug Monitoring</i> , 1983 , 5, 363-6	3.2	15
36	Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 301-7	6.1	67
35	Bleomycin disposition in children with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 668-73	6.1	17
34	Clinical pharmacology of bleomycin and cisplatin. <i>Drug Intelligence & Clinical Pharmacy</i> , 1982 , 16, 448-58		9
33	Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia. <i>Drug Intelligence & Clinical Pharmacy</i> , 1982 , 16, 839-42		21
32	ACCP Forms Specialty Committee. <i>American Journal of Health-System Pharmacy</i> , 1982 , 39, 44-46	2.2	
31	Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. <i>Cancer</i> , 1982 , 49, 1378-83	6.4	93
30	High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrexate, 4-deoxy-4-amino-N10-methylpterotic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. <i>Biomedical Applications</i> , 1982 , 231, 103-10		18
29	Quantitation of daunorubicin and its metabolites by high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1982 , 232, 377-83		23
28	Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1982 , 7, 147-50	3.5	87
27	Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides. <i>Pharmacotherapy</i> , 1981 , 1, 55-75	5.8	22
26	Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. <i>Cancer</i> , 1981 , 48, 1715-8	6.4	95

25	Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. <i>Journal of Pharmaceutical Sciences</i> , 1981 , 70, 1194-8	3.9	15
24	Clinical pharmacology of bleomycin and cisplatin. <i>Head & Neck</i> , 1981 , 4, 98-110		20
23	Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. <i>International Journal of Radiation Oncology Biology Physics</i> , 1981 , 7, 953-6	4	13
22	Cisplatin disposition in children and adolescents with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1981 , 6, 95-9	3.5	33
21	The clinical pharmacist and research. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 241-4	2.9	8
20	Accuracy of Using Pre- and Postdose Gentamicin Serum Concentrations to Estimate Pharmacokinetic Parameters and Adjust Doses in Children and Adolescents. <i>Therapeutic Drug Monitoring</i> , 1981 , 3, 57-62	3.2	14
19	A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing. <i>Clinical Pharmacokinetics</i> , 1980 , 5, 295-306	6.2	34
18	PHASE II EVALUATION OF CISPLATIN IN CHILDREN WITH NEUROBLASTOMA AND OTHER MALIGNANT SOLID TUMORS 1980 , 477-484		2
17	Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1979 , 3, 161-6	3.5	89
16	Gentamicin dosage in children: a randomized prospective comparison of body weight and body surface area as dose determinants. <i>Journal of Pediatrics</i> , 1979 , 94, 139-43	3.6	14
15	Use of gentamicin serum levels to individualize therapy in children. <i>Journal of Pediatrics</i> , 1978 , 93, 133-7	3.6	24
14	Treatment of the Totally Occluded Abdominal Aorta. <i>Vascular Surgery</i> , 1978 , 12, 287-293		
13	Effect of pleural effusion on high-dose methotrexate kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1978 , 23, 68-72	6.1	70
12	Comparison of Antibiotic Serum Concentrations After Intramuscular Oxacillin and Oral Cloxacillin in Children. <i>American Journal of Health-System Pharmacy</i> , 1978 , 35, 1380-1382	2.2	
11	Lead poisoning from ingestion of Chinese herbal medicine. <i>Clinical Toxicology</i> , 1977 , 10, 273-81		32
10	Microbiological Hazards of Infusion Therapy. <i>American Journal of Health-System Pharmacy</i> , 1977 , 34, 775-775	2.2	
9	Unit dose radiopharmaceutical service as a component of total pharmacy practice. <i>American Journal of Health-System Pharmacy</i> , 1976 , 33, 61-63	2.2	
8	Double-blind evaluation of 5- β final filtration to reduce postinfusion phlebitis. <i>American Journal of Health-System Pharmacy</i> , 1976 , 33, 1160-1163	2.2	1

- 7 Phenobarbital-Induced Hepatic Dysfunction. *Drug Intelligence & Clinical Pharmacy*, **1976**, 10, 439-443 11
- 6 Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole. *Drug Intelligence & Clinical Pharmacy*, **1975**, 9, 660-662
- 5 Chloral Hydrate-Warfarin Interaction. *American Journal of Health-System Pharmacy*, **1975**, 32, 241-243 2.2
- 4 Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations309-331
- 3 Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations391-413 1
- 2 Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia 3
- 1 Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing 5